Skin & cosmetic
RU-58841
Topical antiandrogen · topical · anti-DHT
A topical anti-DHT compound for hair retention, developed but never brought to full approval — strong anecdotal history, no completed human trials published.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
RU-58841 was developed as a topical antiandrogen intended to block DHT's effect at the hair follicle without the systemic hormonal effects of oral antiandrogens. Early development showed promise, but it was never taken through to a completed, published clinical trial or product approval.
It has a long history of anecdotal use in hair-loss communities, compounded into topical solutions by specialist suppliers, with a large body of user-reported (not clinically trialled) experience.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Reduces DHT's effect at the hair follicle, slowing hair loss”
Plausible and consistent with its design mechanism; no completed, published human RCT exists.
Claim-level citation mapping is in progress.
“Works without systemic hormonal side effects”
The design intent and widely reported user experience, but not confirmed in a formal trial.
Claim-level citation mapping is in progress.
“A proven, approved hair-loss treatment”
It was never approved anywhere — development stalled before reaching that stage.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Not a licensed medicine or approved cosmetic ingredient in the UK. Sold as a research chemical/compounded topical, with no formal approval route.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
A long-standing staple of hair-loss forums, often discussed alongside minoxidil and finasteride as a topical-only alternative. Large anecdotal base, openly acknowledged lack of formal trials.
Where they’re talking
- Hair-loss forumsLong-running compounding-and-dosing discussion threads.
- r/tresslessFrequently compared with minoxidil/finasteride.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency